ANXA2P2 could be a novel and suitable predicative biomarker for the risk assessment of recurrence or metastasis of HCC patients but may not be effective to predict the efficacy of targeted drugs. The gene discussed is ANXA2P2; the disease is hepatocellular carcinoma.